<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01280643</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 09-033</org_study_id>
    <secondary_id>NCI-2011-00046</secondary_id>
    <nct_id>NCT01280643</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer</brief_title>
  <official_title>An Exploratory Study of Chemotherapy for Metastatic Colorectal Cancer Based Upon Thymidine Phosphorylase Expression, KRAS and BRAF Mutation Status, and ERCC1 Expression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fox Chase Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fox Chase Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin calcium, oxaliplatin,&#xD;
      capecitabine, and irinotecan hydrochloride, work in different ways to stop the growth of&#xD;
      tumor cells, either by killing the cells or by stopping them from dividing. Giving more than&#xD;
      one drug (combination chemotherapy) and giving the drugs in different combinations may kill&#xD;
      more tumor cells. Monoclonal antibodies, such as bevacizumab and cetuximab, can block tumor&#xD;
      growth in different ways. Some block the ability of tumor cells to grow and spread. Others&#xD;
      find tumor cells and help kill them or carry tumor-killing substances to them. Giving&#xD;
      combination chemotherapy together with bevacizumab or cetuximab may kill more tumor cells.&#xD;
&#xD;
      PURPOSE:To evaluate the use of standard (KRAS) and experimental (thymidine phosphorylase,&#xD;
      ERCC1 and BRAF) tumor testing can aid in selecting chemotherapy regimens&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the feasibility, as defined by completion of three specific marker assays and&#xD;
      generation of clinically meaningful endpoints, of selecting treatment regimen components&#xD;
      based on biologic tumor characteristics in chemotherapy-na√Øve patients with metastatic&#xD;
      colorectal cancer.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To investigate the response rate associated with genotype/phenotype guided therapy using&#xD;
      Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.&#xD;
&#xD;
      II. To investigate the time to failure of treatment strategy associated with&#xD;
      genotype/phenotype guided therapy, defined as the time from initiation of investigational&#xD;
      treatment strategy until death, disease progression, initiation of a new therapeutic agent,&#xD;
      or disease progression while on a partial or complete treatment holiday.&#xD;
&#xD;
      III. To investigate the progression-free survival associated with genotype/phenotype guided&#xD;
      therapy, defined as the time from enrollment to time of progression of disease or death.&#xD;
&#xD;
      OUTLINE: Patients are assigned to treatment groups based on marker assay results.&#xD;
&#xD;
      ARM A: TP-/uncertain, KRAS and BRAF wild-type, ERCC1 high ARM B: TP-/uncertain, KRAS and BRAF&#xD;
      wild-type, ERCC1 low/uncertain ARM C: TP-/uncertain, KRAS or BRAF mutant/uncertain, ERCC1&#xD;
      high ARM D: TP-/uncertain, KRAS or BRAF mutant/uncertain, ERCC1 low/uncertain ARM E: TP+,&#xD;
      KRAS and BRAF wild-type, ERCC1 high ARM F: TP+, KRAS and BRAF wild-type, ERCC1 low/uncertain&#xD;
      ARM G: TP+, KRAS or BRAF mutant/uncertain, ERCC1 high ARM H: TP+, KRAS or BRAF&#xD;
      mutant/uncertain, ERCC1 low/uncertain ARM I: TP uninterpretable, KRAS or BRAF&#xD;
      uninterpretable, ERCC1 uninterpretable&#xD;
&#xD;
      KRAS testing is standard of care in patients with metastatic colorectal cancer; tymidine&#xD;
      phosphorylase, ERCC1 and BRAF testing assays are still experimental.&#xD;
&#xD;
      Courses in arms A-D and arm I repeat every 28 days and courses in arms E-H repeat every 21&#xD;
      days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3 months for 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual&#xD;
  </why_stopped>
  <start_date type="Actual">March 2010</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility, Defined as a Sufficient Proportion of Subjects Having Available Tissue and an Acceptable Composite Assay Success Rate Among Tested Subjects</measure>
    <time_frame>Over 21 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response Via RECIST</measure>
    <time_frame>Over 21 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Failure of Treatment Strategy</measure>
    <time_frame>Over 21 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>Over 21 months</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive FOLFIRI (FOLolinic acid (leucovorin) Fluorouracil (5-FU) IRInotecan (irinotecan)) chemotherapy comprising fluorouracil intravenously (IV) over 46 hours continuously, leucovorin calcium IV over 2 hours, and irinotecan hydrochloride IV over 90 minutes on days 1 and 15. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive FOLFOX (FOL- Folinic acid (leucovorin) F - Fluorouracil (5-FU) OX - Oxaliplatin (Eloxatin)) chemotherapy comprising fluorouracil IV over 46 hours continuously on day 1 and leucovorin calcium IV over 2 hours and oxaliplatin IV over 2 hours on days 1 and 15. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive FOLFIRI chemotherapy as in Arm A and bevacizumab IV over 30-90 minutes on days 1 and 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive FOLFOX chemotherapy as in Arm B and bevacizumab IV over 30-90 minutes on days 1 and 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive CapeIRI (Capecitabine and Irinotecan) chemotherapy comprising capecitabine orally (PO) twice daily (BID) on days 1-14 and irinotecan hydrochloride IV over 90 minutes on days 1 and 8. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive CapeOX (capecitabine (Xeloda) and oxaliplatin (Eloxatin)) chemotherapy comprising capecitabine PO BID on days 1-14 and oxaliplatin IV over 2 hours on day 1. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive CapeIRI chemotherapy as in Arm E and bevacizumab IV over 30-90 minutes on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm H</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive CapeOX chemotherapy as in Arm F and bevacizumab IV over 30-90 minutes on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive treatment as in Arm D.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>5-fluorouracil</other_name>
    <other_name>5-Fluracil</other_name>
    <other_name>5-FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>CF</other_name>
    <other_name>CFR</other_name>
    <other_name>LV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_label>Arm F</arm_group_label>
    <arm_group_label>Arm H</arm_group_label>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>1-OHP</other_name>
    <other_name>Dacotin</other_name>
    <other_name>Dacplat</other_name>
    <other_name>Eloxatin</other_name>
    <other_name>L-OHP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>ARM G</arm_group_label>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm E</arm_group_label>
    <other_name>Campto</other_name>
    <other_name>Camptosar</other_name>
    <other_name>CPT-11</other_name>
    <other_name>irinotecan</other_name>
    <other_name>U-101440E</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>ARM G</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_label>Arm H</arm_group_label>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>anti-VEGF humanized monoclonal antibody</other_name>
    <other_name>anti-VEGF monoclonal antibody</other_name>
    <other_name>Avastin</other_name>
    <other_name>rhuMAb VEGF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm E</arm_group_label>
    <arm_group_label>Arm F</arm_group_label>
    <other_name>C225</other_name>
    <other_name>C225 monoclonal antibody</other_name>
    <other_name>IMC-C225</other_name>
    <other_name>MOAB C225</other_name>
    <other_name>monoclonal antibody C225</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>ARM G</arm_group_label>
    <arm_group_label>Arm E</arm_group_label>
    <arm_group_label>Arm F</arm_group_label>
    <arm_group_label>Arm H</arm_group_label>
    <other_name>CAPE</other_name>
    <other_name>Ro 09-1978/000</other_name>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>mutation analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>ARM G</arm_group_label>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_label>Arm E</arm_group_label>
    <arm_group_label>Arm F</arm_group_label>
    <arm_group_label>Arm H</arm_group_label>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>ARM G</arm_group_label>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_label>Arm E</arm_group_label>
    <arm_group_label>Arm F</arm_group_label>
    <arm_group_label>Arm H</arm_group_label>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>ARM G</arm_group_label>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_label>Arm E</arm_group_label>
    <arm_group_label>Arm F</arm_group_label>
    <arm_group_label>Arm H</arm_group_label>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>ARM G</arm_group_label>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_label>Arm E</arm_group_label>
    <arm_group_label>Arm F</arm_group_label>
    <arm_group_label>Arm H</arm_group_label>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>immunohistochemistry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>nucleic acid sequencing</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>ARM G</arm_group_label>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_label>Arm E</arm_group_label>
    <arm_group_label>Arm F</arm_group_label>
    <arm_group_label>Arm H</arm_group_label>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Gene Sequencing</other_name>
    <other_name>Molecular Biology, Nucleic Acid Sequencing</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein expression analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>ARM G</arm_group_label>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_label>Arm E</arm_group_label>
    <arm_group_label>Arm F</arm_group_label>
    <arm_group_label>Arm H</arm_group_label>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>ARM G</arm_group_label>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_label>Arm E</arm_group_label>
    <arm_group_label>Arm F</arm_group_label>
    <arm_group_label>Arm H</arm_group_label>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>PCR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>ARM G</arm_group_label>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_label>Arm E</arm_group_label>
    <arm_group_label>Arm F</arm_group_label>
    <arm_group_label>Arm H</arm_group_label>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically confirmed colon or rectal cancer that has&#xD;
             metastasized; no biopsy of metastatic site(s) are required if presentation is&#xD;
             consistent with metastatic disease&#xD;
&#xD;
          -  Available archived tissue block or slides from the primary colon or rectal cancer;&#xD;
             approximately 25 slides from the primary tumor tissue are necessary for testing of all&#xD;
             markers&#xD;
&#xD;
          -  Patients must have measurable disease by RECIST 1.1, defined as at least one lesion&#xD;
             that can be accurately measured in at least one dimension (longest diameter to be&#xD;
             recorded) as &gt;= 10 mm with computed tomography (CT) scan or clinical exam with&#xD;
             calipers; lymph nodes must be 15 mm in shortest dimension as measured on CT scan&#xD;
&#xD;
          -  Patients may not have received prior therapy for metastatic colorectal cancer; prior&#xD;
             adjuvant therapy (including any of the study agents) is permitted if completed &gt; 6&#xD;
             months from the initial detection of metastatic disease&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/mcL&#xD;
&#xD;
          -  Platelets &gt;= 100,000/mcL&#xD;
&#xD;
          -  Total bilirubin =&lt; 2 X institutional upper limit of normal (ULN)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/&#xD;
             alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =&lt; 3 X&#xD;
             institutional ULN or =&lt; 5 X ULN if known liver metastases&#xD;
&#xD;
          -  Creatinine clearance &gt;= 50 mL/min (as calculated by Cockroft and Gault formula)&#xD;
&#xD;
          -  Urine protein:creatinine (UPC) ratio &lt; 1.0 at screening (as calculated from urine&#xD;
             protein concentration and urine creatinine concentration); patients with a UPC ratio&#xD;
             &gt;= 1 will undergo a 24-hour urine collection, which must be adequate and demonstrate &lt;&#xD;
             1 gram in order to participate&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have had previous chemotherapy for metastatic colorectal cancer&#xD;
&#xD;
          -  Uncontrolled hypertension (&gt;150/100 mmHg) despite a stable regimen of&#xD;
             anti-hypertensive medication&#xD;
&#xD;
          -  History of cardiovascular disease, defined as previous myocardial infarction,&#xD;
             cerebrovascular accident, uncontrolled congestive heart failure (New York Heart&#xD;
             Association &gt; Class II), clinically significant ventricular arrhythmia requiring&#xD;
             medication, clinically significant peripheral vascular disease, or unstable angina&#xD;
             within 6 months of study enrollment&#xD;
&#xD;
          -  Underlying neuropathy &gt;= grade 2&#xD;
&#xD;
          -  Serious non-healing wounds, ulcers, or fistulas&#xD;
&#xD;
          -  Major surgery, open biopsy, or major traumatic injury within 28 days of registration,&#xD;
             or anticipation of need for surgical procedure during course of study, and core biopsy&#xD;
             or fine needle aspiration within 7 days of registration; closed biopsy or access port&#xD;
             placement is acceptable&#xD;
&#xD;
          -  A history of thrombotic or hemorrhagic disorder; patients with elevated international&#xD;
             normalized ratio (INR) (2.0 to 3.0) on stable doses of therapeutic anticoagulation are&#xD;
             eligible&#xD;
&#xD;
          -  Untreated brain metastases; patients with treated brain metastases who have completed&#xD;
             radiation therapy, are clinically and radiographically stable, and are off steroid&#xD;
             therapy may be enrolled&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to cetuximab, oxaliplatin, capecitabine, or other agents used in the study&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          -  Pregnant women are excluded; breastfeeding should be discontinued if the mother is&#xD;
             treated with chemotherapy&#xD;
&#xD;
          -  Human Immunodeficiency Virus (HIV)-positive patients on combination antiretroviral&#xD;
             therapy are ineligible; appropriate studies will be undertaken in patients receiving&#xD;
             combination antiretroviral therapy when indicated&#xD;
&#xD;
          -  Patients must not have a history of another neoplasm &lt; 5 years prior to enrollment,&#xD;
             except for non-metastatic, non-melanoma skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  Patients of child-bearing potential who are unwilling or unable to utilize&#xD;
             contraceptive measures including barrier contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Crystal Denlinger</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fox Chase Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111-2497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 20, 2011</study_first_submitted>
  <study_first_submitted_qc>January 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2011</study_first_posted>
  <results_first_submitted>February 3, 2021</results_first_submitted>
  <results_first_submitted_qc>February 22, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 15, 2021</results_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IVA colon cancer</keyword>
  <keyword>stage IVA rectal cancer</keyword>
  <keyword>stage IVB colon cancer</keyword>
  <keyword>stage IVB rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm A</title>
          <description>Patients receive FOLFIRI (FOLolinic acid (leucovorin) Fluorouracil (5-FU) IRInotecan (irinotecan)) chemotherapy comprising fluorouracil intravenously (IV) over 46 hours continuously, leucovorin calcium IV over 2 hours, and irinotecan hydrochloride IV over 90 minutes on days 1 and 15. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.&#xD;
fluorouracil: Given IV&#xD;
leucovorin calcium: Given IV&#xD;
irinotecan hydrochloride: Given IV&#xD;
cetuximab: Given IV&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
        </group>
        <group group_id="P2">
          <title>Arm B</title>
          <description>Patients receive FOLFOX (FOL- Folinic acid (leucovorin) F - Fluorouracil (5-FU) OX - Oxaliplatin (Eloxatin)) chemotherapy comprising fluorouracil IV over 46 hours continuously on day 1 and leucovorin calcium IV over 2 hours and oxaliplatin IV over 2 hours on days 1 and 15. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.&#xD;
fluorouracil: Given IV&#xD;
leucovorin calcium: Given IV&#xD;
oxaliplatin: Given IV&#xD;
cetuximab: Given IV&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
        </group>
        <group group_id="P3">
          <title>Arm C</title>
          <description>Patients receive FOLFIRI chemotherapy as in Arm A and bevacizumab IV over 30-90 minutes on days 1 and 15.&#xD;
fluorouracil: Given IV&#xD;
leucovorin calcium: Given IV&#xD;
irinotecan hydrochloride: Given IV&#xD;
bevacizumab: Given IV&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
        </group>
        <group group_id="P4">
          <title>Arm D</title>
          <description>Patients receive FOLFOX chemotherapy as in Arm B and bevacizumab IV over 30-90 minutes on days 1 and 15.&#xD;
fluorouracil: Given IV&#xD;
leucovorin calcium: Given IV&#xD;
oxaliplatin: Given IV&#xD;
bevacizumab: Given IV&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
        </group>
        <group group_id="P5">
          <title>Arm E</title>
          <description>Patients receive CapeIRI (Capecitabine and Irinotecan) chemotherapy comprising capecitabine orally (PO) twice daily (BID) on days 1-14 and irinotecan hydrochloride IV over 90 minutes on days 1 and 8. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.&#xD;
irinotecan hydrochloride: Given IV&#xD;
cetuximab: Given IV&#xD;
capecitabine: Given PO&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
        </group>
        <group group_id="P6">
          <title>Arm F</title>
          <description>Patients receive CapeOX (capecitabine (Xeloda) and oxaliplatin (Eloxatin)) chemotherapy comprising capecitabine PO BID on days 1-14 and oxaliplatin IV over 2 hours on day 1. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.&#xD;
oxaliplatin: Given IV&#xD;
cetuximab: Given IV&#xD;
capecitabine: Given PO&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
        </group>
        <group group_id="P7">
          <title>ARM G</title>
          <description>Patients receive CapeIRI chemotherapy as in Arm E and bevacizumab IV over 30-90 minutes on day 1.&#xD;
irinotecan hydrochloride: Given IV&#xD;
bevacizumab: Given IV&#xD;
capecitabine: Given PO&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
        </group>
        <group group_id="P8">
          <title>Arm H</title>
          <description>Patients receive CapeOX chemotherapy as in Arm F and bevacizumab IV over 30-90 minutes on day 1.&#xD;
oxaliplatin: Given IV&#xD;
bevacizumab: Given IV&#xD;
capecitabine: Given PO&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
        </group>
        <group group_id="P9">
          <title>Arm I</title>
          <description>Patients receive treatment as in Arm D.&#xD;
fluorouracil: Given IV&#xD;
leucovorin calcium: Given IV&#xD;
oxaliplatin: Given IV&#xD;
bevacizumab: Given IV&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Study closed prematurely due to poor accrual</population>
      <group_list>
        <group group_id="B1">
          <title>Arm A</title>
          <description>Patients receive FOLFIRI (FOLolinic acid (leucovorin) Fluorouracil (5-FU) IRInotecan (irinotecan)) chemotherapy comprising fluorouracil intravenously (IV) over 46 hours continuously, leucovorin calcium IV over 2 hours, and irinotecan hydrochloride IV over 90 minutes on days 1 and 15. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.&#xD;
fluorouracil: Given IV&#xD;
leucovorin calcium: Given IV&#xD;
irinotecan hydrochloride: Given IV&#xD;
cetuximab: Given IV&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
        </group>
        <group group_id="B2">
          <title>Arm B</title>
          <description>Patients receive FOLFOX (FOL- Folinic acid (leucovorin) F - Fluorouracil (5-FU) OX - Oxaliplatin (Eloxatin)) chemotherapy comprising fluorouracil IV over 46 hours continuously on day 1 and leucovorin calcium IV over 2 hours and oxaliplatin IV over 2 hours on days 1 and 15. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.&#xD;
fluorouracil: Given IV&#xD;
leucovorin calcium: Given IV&#xD;
oxaliplatin: Given IV&#xD;
cetuximab: Given IV&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
        </group>
        <group group_id="B3">
          <title>Arm C</title>
          <description>Patients receive FOLFIRI chemotherapy as in Arm A and bevacizumab IV over 30-90 minutes on days 1 and 15.&#xD;
fluorouracil: Given IV&#xD;
leucovorin calcium: Given IV&#xD;
irinotecan hydrochloride: Given IV&#xD;
bevacizumab: Given IV&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
        </group>
        <group group_id="B4">
          <title>Arm D</title>
          <description>Patients receive FOLFOX chemotherapy as in Arm B and bevacizumab IV over 30-90 minutes on days 1 and 15.&#xD;
fluorouracil: Given IV&#xD;
leucovorin calcium: Given IV&#xD;
oxaliplatin: Given IV&#xD;
bevacizumab: Given IV&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
        </group>
        <group group_id="B5">
          <title>Arm E</title>
          <description>Patients receive CapeIRI (Capecitabine and Irinotecan) chemotherapy comprising capecitabine orally (PO) twice daily (BID) on days 1-14 and irinotecan hydrochloride IV over 90 minutes on days 1 and 8. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.&#xD;
irinotecan hydrochloride: Given IV&#xD;
cetuximab: Given IV&#xD;
capecitabine: Given PO&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
        </group>
        <group group_id="B6">
          <title>Arm F</title>
          <description>Patients receive CapeOX (capecitabine (Xeloda) and oxaliplatin (Eloxatin)) chemotherapy comprising capecitabine PO BID on days 1-14 and oxaliplatin IV over 2 hours on day 1. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.&#xD;
oxaliplatin: Given IV&#xD;
cetuximab: Given IV&#xD;
capecitabine: Given PO&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
        </group>
        <group group_id="B7">
          <title>ARM G</title>
          <description>Patients receive CapeIRI chemotherapy as in Arm E and bevacizumab IV over 30-90 minutes on day 1.&#xD;
irinotecan hydrochloride: Given IV&#xD;
bevacizumab: Given IV&#xD;
capecitabine: Given PO&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
        </group>
        <group group_id="B8">
          <title>Arm H</title>
          <description>Patients receive CapeOX chemotherapy as in Arm F and bevacizumab IV over 30-90 minutes on day 1.&#xD;
oxaliplatin: Given IV&#xD;
bevacizumab: Given IV&#xD;
capecitabine: Given PO&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
        </group>
        <group group_id="B9">
          <title>Arm I</title>
          <description>Patients receive treatment as in Arm D.&#xD;
fluorouracil: Given IV&#xD;
leucovorin calcium: Given IV&#xD;
oxaliplatin: Given IV&#xD;
bevacizumab: Given IV&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="1"/>
            <count group_id="B4" value="1"/>
            <count group_id="B5" value="0"/>
            <count group_id="B6" value="0"/>
            <count group_id="B7" value="0"/>
            <count group_id="B8" value="0"/>
            <count group_id="B9" value="0"/>
            <count group_id="B10" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B10" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B10" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B10" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Feasibility, Defined as a Sufficient Proportion of Subjects Having Available Tissue and an Acceptable Composite Assay Success Rate Among Tested Subjects</title>
        <time_frame>Over 21 months</time_frame>
        <population>Too few enrolled participants for meaningful analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Patients receive FOLFIRI (FOLolinic acid (leucovorin) Fluorouracil (5-FU) IRInotecan (irinotecan)) chemotherapy comprising fluorouracil intravenously (IV) over 46 hours continuously, leucovorin calcium IV over 2 hours, and irinotecan hydrochloride IV over 90 minutes on days 1 and 15. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.&#xD;
fluorouracil: Given IV&#xD;
leucovorin calcium: Given IV&#xD;
irinotecan hydrochloride: Given IV&#xD;
cetuximab: Given IV&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Patients receive FOLFOX (FOL- Folinic acid (leucovorin) F - Fluorouracil (5-FU) OX - Oxaliplatin (Eloxatin)) chemotherapy comprising fluorouracil IV over 46 hours continuously on day 1 and leucovorin calcium IV over 2 hours and oxaliplatin IV over 2 hours on days 1 and 15. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.&#xD;
fluorouracil: Given IV&#xD;
leucovorin calcium: Given IV&#xD;
oxaliplatin: Given IV&#xD;
cetuximab: Given IV&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
          </group>
          <group group_id="O3">
            <title>Arm C</title>
            <description>Patients receive FOLFIRI chemotherapy as in Arm A and bevacizumab IV over 30-90 minutes on days 1 and 15.&#xD;
fluorouracil: Given IV&#xD;
leucovorin calcium: Given IV&#xD;
irinotecan hydrochloride: Given IV&#xD;
bevacizumab: Given IV&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
          </group>
          <group group_id="O4">
            <title>Arm D</title>
            <description>Patients receive FOLFOX chemotherapy as in Arm B and bevacizumab IV over 30-90 minutes on days 1 and 15.&#xD;
fluorouracil: Given IV&#xD;
leucovorin calcium: Given IV&#xD;
oxaliplatin: Given IV&#xD;
bevacizumab: Given IV&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
          </group>
          <group group_id="O5">
            <title>Arm E</title>
            <description>Patients receive CapeIRI (Capecitabine and Irinotecan) chemotherapy comprising capecitabine orally (PO) twice daily (BID) on days 1-14 and irinotecan hydrochloride IV over 90 minutes on days 1 and 8. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.&#xD;
irinotecan hydrochloride: Given IV&#xD;
cetuximab: Given IV&#xD;
capecitabine: Given PO&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
          </group>
          <group group_id="O6">
            <title>Arm F</title>
            <description>Patients receive CapeOX (capecitabine (Xeloda) and oxaliplatin (Eloxatin)) chemotherapy comprising capecitabine PO BID on days 1-14 and oxaliplatin IV over 2 hours on day 1. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.&#xD;
oxaliplatin: Given IV&#xD;
cetuximab: Given IV&#xD;
capecitabine: Given PO&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
          </group>
          <group group_id="O7">
            <title>ARM G</title>
            <description>Patients receive CapeIRI chemotherapy as in Arm E and bevacizumab IV over 30-90 minutes on day 1.&#xD;
irinotecan hydrochloride: Given IV&#xD;
bevacizumab: Given IV&#xD;
capecitabine: Given PO&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
          </group>
          <group group_id="O8">
            <title>Arm H</title>
            <description>Patients receive CapeOX chemotherapy as in Arm F and bevacizumab IV over 30-90 minutes on day 1.&#xD;
oxaliplatin: Given IV&#xD;
bevacizumab: Given IV&#xD;
capecitabine: Given PO&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
          </group>
          <group group_id="O9">
            <title>Arm I</title>
            <description>Patients receive treatment as in Arm D.&#xD;
fluorouracil: Given IV&#xD;
leucovorin calcium: Given IV&#xD;
oxaliplatin: Given IV&#xD;
bevacizumab: Given IV&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility, Defined as a Sufficient Proportion of Subjects Having Available Tissue and an Acceptable Composite Assay Success Rate Among Tested Subjects</title>
          <population>Too few enrolled participants for meaningful analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Overall Response Via RECIST</title>
        <time_frame>Over 21 months</time_frame>
        <population>Too few enrolled participants for meaningful analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Patients receive FOLFIRI (FOLolinic acid (leucovorin) Fluorouracil (5-FU) IRInotecan (irinotecan)) chemotherapy comprising fluorouracil intravenously (IV) over 46 hours continuously, leucovorin calcium IV over 2 hours, and irinotecan hydrochloride IV over 90 minutes on days 1 and 15. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.&#xD;
fluorouracil: Given IV&#xD;
leucovorin calcium: Given IV&#xD;
irinotecan hydrochloride: Given IV&#xD;
cetuximab: Given IV&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Patients receive FOLFOX (FOL- Folinic acid (leucovorin) F - Fluorouracil (5-FU) OX - Oxaliplatin (Eloxatin)) chemotherapy comprising fluorouracil IV over 46 hours continuously on day 1 and leucovorin calcium IV over 2 hours and oxaliplatin IV over 2 hours on days 1 and 15. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.&#xD;
fluorouracil: Given IV&#xD;
leucovorin calcium: Given IV&#xD;
oxaliplatin: Given IV&#xD;
cetuximab: Given IV&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
          </group>
          <group group_id="O3">
            <title>Arm C</title>
            <description>Patients receive FOLFIRI chemotherapy as in Arm A and bevacizumab IV over 30-90 minutes on days 1 and 15.&#xD;
fluorouracil: Given IV&#xD;
leucovorin calcium: Given IV&#xD;
irinotecan hydrochloride: Given IV&#xD;
bevacizumab: Given IV&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
          </group>
          <group group_id="O4">
            <title>Arm D</title>
            <description>Patients receive FOLFOX chemotherapy as in Arm B and bevacizumab IV over 30-90 minutes on days 1 and 15.&#xD;
fluorouracil: Given IV&#xD;
leucovorin calcium: Given IV&#xD;
oxaliplatin: Given IV&#xD;
bevacizumab: Given IV&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
          </group>
          <group group_id="O5">
            <title>Arm E</title>
            <description>Patients receive CapeIRI (Capecitabine and Irinotecan) chemotherapy comprising capecitabine orally (PO) twice daily (BID) on days 1-14 and irinotecan hydrochloride IV over 90 minutes on days 1 and 8. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.&#xD;
irinotecan hydrochloride: Given IV&#xD;
cetuximab: Given IV&#xD;
capecitabine: Given PO&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
          </group>
          <group group_id="O6">
            <title>Arm F</title>
            <description>Patients receive CapeOX (capecitabine (Xeloda) and oxaliplatin (Eloxatin)) chemotherapy comprising capecitabine PO BID on days 1-14 and oxaliplatin IV over 2 hours on day 1. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.&#xD;
oxaliplatin: Given IV&#xD;
cetuximab: Given IV&#xD;
capecitabine: Given PO&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
          </group>
          <group group_id="O7">
            <title>ARM G</title>
            <description>Patients receive CapeIRI chemotherapy as in Arm E and bevacizumab IV over 30-90 minutes on day 1.&#xD;
irinotecan hydrochloride: Given IV&#xD;
bevacizumab: Given IV&#xD;
capecitabine: Given PO&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
          </group>
          <group group_id="O8">
            <title>Arm H</title>
            <description>Patients receive CapeOX chemotherapy as in Arm F and bevacizumab IV over 30-90 minutes on day 1.&#xD;
oxaliplatin: Given IV&#xD;
bevacizumab: Given IV&#xD;
capecitabine: Given PO&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
          </group>
          <group group_id="O9">
            <title>Arm I</title>
            <description>Patients receive treatment as in Arm D.&#xD;
fluorouracil: Given IV&#xD;
leucovorin calcium: Given IV&#xD;
oxaliplatin: Given IV&#xD;
bevacizumab: Given IV&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Best Overall Response Via RECIST</title>
          <population>Too few enrolled participants for meaningful analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Failure of Treatment Strategy</title>
        <time_frame>Over 21 months</time_frame>
        <population>Too few enrolled participants for meaningful analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Patients receive FOLFIRI (FOLolinic acid (leucovorin) Fluorouracil (5-FU) IRInotecan (irinotecan)) chemotherapy comprising fluorouracil intravenously (IV) over 46 hours continuously, leucovorin calcium IV over 2 hours, and irinotecan hydrochloride IV over 90 minutes on days 1 and 15. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.&#xD;
fluorouracil: Given IV&#xD;
leucovorin calcium: Given IV&#xD;
irinotecan hydrochloride: Given IV&#xD;
cetuximab: Given IV&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Patients receive FOLFOX (FOL- Folinic acid (leucovorin) F - Fluorouracil (5-FU) OX - Oxaliplatin (Eloxatin)) chemotherapy comprising fluorouracil IV over 46 hours continuously on day 1 and leucovorin calcium IV over 2 hours and oxaliplatin IV over 2 hours on days 1 and 15. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.&#xD;
fluorouracil: Given IV&#xD;
leucovorin calcium: Given IV&#xD;
oxaliplatin: Given IV&#xD;
cetuximab: Given IV&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
          </group>
          <group group_id="O3">
            <title>Arm C</title>
            <description>Patients receive FOLFIRI chemotherapy as in Arm A and bevacizumab IV over 30-90 minutes on days 1 and 15.&#xD;
fluorouracil: Given IV&#xD;
leucovorin calcium: Given IV&#xD;
irinotecan hydrochloride: Given IV&#xD;
bevacizumab: Given IV&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
          </group>
          <group group_id="O4">
            <title>Arm D</title>
            <description>Patients receive FOLFOX chemotherapy as in Arm B and bevacizumab IV over 30-90 minutes on days 1 and 15.&#xD;
fluorouracil: Given IV&#xD;
leucovorin calcium: Given IV&#xD;
oxaliplatin: Given IV&#xD;
bevacizumab: Given IV&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
          </group>
          <group group_id="O5">
            <title>Arm E</title>
            <description>Patients receive CapeIRI (Capecitabine and Irinotecan) chemotherapy comprising capecitabine orally (PO) twice daily (BID) on days 1-14 and irinotecan hydrochloride IV over 90 minutes on days 1 and 8. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.&#xD;
irinotecan hydrochloride: Given IV&#xD;
cetuximab: Given IV&#xD;
capecitabine: Given PO&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
          </group>
          <group group_id="O6">
            <title>Arm F</title>
            <description>Patients receive CapeOX (capecitabine (Xeloda) and oxaliplatin (Eloxatin)) chemotherapy comprising capecitabine PO BID on days 1-14 and oxaliplatin IV over 2 hours on day 1. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.&#xD;
oxaliplatin: Given IV&#xD;
cetuximab: Given IV&#xD;
capecitabine: Given PO&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
          </group>
          <group group_id="O7">
            <title>ARM G</title>
            <description>Patients receive CapeIRI chemotherapy as in Arm E and bevacizumab IV over 30-90 minutes on day 1.&#xD;
irinotecan hydrochloride: Given IV&#xD;
bevacizumab: Given IV&#xD;
capecitabine: Given PO&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
          </group>
          <group group_id="O8">
            <title>Arm H</title>
            <description>Patients receive CapeOX chemotherapy as in Arm F and bevacizumab IV over 30-90 minutes on day 1.&#xD;
oxaliplatin: Given IV&#xD;
bevacizumab: Given IV&#xD;
capecitabine: Given PO&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
          </group>
          <group group_id="O9">
            <title>Arm I</title>
            <description>Patients receive treatment as in Arm D.&#xD;
fluorouracil: Given IV&#xD;
leucovorin calcium: Given IV&#xD;
oxaliplatin: Given IV&#xD;
bevacizumab: Given IV&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Failure of Treatment Strategy</title>
          <population>Too few enrolled participants for meaningful analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <time_frame>Over 21 months</time_frame>
        <population>Too few enrolled participants for meaningful analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Patients receive FOLFIRI (FOLolinic acid (leucovorin) Fluorouracil (5-FU) IRInotecan (irinotecan)) chemotherapy comprising fluorouracil intravenously (IV) over 46 hours continuously, leucovorin calcium IV over 2 hours, and irinotecan hydrochloride IV over 90 minutes on days 1 and 15. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.&#xD;
fluorouracil: Given IV&#xD;
leucovorin calcium: Given IV&#xD;
irinotecan hydrochloride: Given IV&#xD;
cetuximab: Given IV&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Patients receive FOLFOX (FOL- Folinic acid (leucovorin) F - Fluorouracil (5-FU) OX - Oxaliplatin (Eloxatin)) chemotherapy comprising fluorouracil IV over 46 hours continuously on day 1 and leucovorin calcium IV over 2 hours and oxaliplatin IV over 2 hours on days 1 and 15. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.&#xD;
fluorouracil: Given IV&#xD;
leucovorin calcium: Given IV&#xD;
oxaliplatin: Given IV&#xD;
cetuximab: Given IV&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
          </group>
          <group group_id="O3">
            <title>Arm C</title>
            <description>Patients receive FOLFIRI chemotherapy as in Arm A and bevacizumab IV over 30-90 minutes on days 1 and 15.&#xD;
fluorouracil: Given IV&#xD;
leucovorin calcium: Given IV&#xD;
irinotecan hydrochloride: Given IV&#xD;
bevacizumab: Given IV&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
          </group>
          <group group_id="O4">
            <title>Arm D</title>
            <description>Patients receive FOLFOX chemotherapy as in Arm B and bevacizumab IV over 30-90 minutes on days 1 and 15.&#xD;
fluorouracil: Given IV&#xD;
leucovorin calcium: Given IV&#xD;
oxaliplatin: Given IV&#xD;
bevacizumab: Given IV&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
          </group>
          <group group_id="O5">
            <title>Arm E</title>
            <description>Patients receive CapeIRI (Capecitabine and Irinotecan) chemotherapy comprising capecitabine orally (PO) twice daily (BID) on days 1-14 and irinotecan hydrochloride IV over 90 minutes on days 1 and 8. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.&#xD;
irinotecan hydrochloride: Given IV&#xD;
cetuximab: Given IV&#xD;
capecitabine: Given PO&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
          </group>
          <group group_id="O6">
            <title>Arm F</title>
            <description>Patients receive CapeOX (capecitabine (Xeloda) and oxaliplatin (Eloxatin)) chemotherapy comprising capecitabine PO BID on days 1-14 and oxaliplatin IV over 2 hours on day 1. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.&#xD;
oxaliplatin: Given IV&#xD;
cetuximab: Given IV&#xD;
capecitabine: Given PO&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
          </group>
          <group group_id="O7">
            <title>ARM G</title>
            <description>Patients receive CapeIRI chemotherapy as in Arm E and bevacizumab IV over 30-90 minutes on day 1.&#xD;
irinotecan hydrochloride: Given IV&#xD;
bevacizumab: Given IV&#xD;
capecitabine: Given PO&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
          </group>
          <group group_id="O8">
            <title>Arm H</title>
            <description>Patients receive CapeOX chemotherapy as in Arm F and bevacizumab IV over 30-90 minutes on day 1.&#xD;
oxaliplatin: Given IV&#xD;
bevacizumab: Given IV&#xD;
capecitabine: Given PO&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
          </group>
          <group group_id="O9">
            <title>Arm I</title>
            <description>Patients receive treatment as in Arm D.&#xD;
fluorouracil: Given IV&#xD;
leucovorin calcium: Given IV&#xD;
oxaliplatin: Given IV&#xD;
bevacizumab: Given IV&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <population>Too few enrolled participants for meaningful analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>No patients accrued to arms A, E, F, G, H, I due to premature study closure resulting from slow accrual</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm A</title>
          <description>Patients receive FOLFIRI (FOLolinic acid (leucovorin) Fluorouracil (5-FU) IRInotecan (irinotecan)) chemotherapy comprising fluorouracil intravenously (IV) over 46 hours continuously, leucovorin calcium IV over 2 hours, and irinotecan hydrochloride IV over 90 minutes on days 1 and 15. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.&#xD;
fluorouracil: Given IV&#xD;
leucovorin calcium: Given IV&#xD;
irinotecan hydrochloride: Given IV&#xD;
cetuximab: Given IV&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
        </group>
        <group group_id="E2">
          <title>Arm B</title>
          <description>Patients receive FOLFOX (FOL- Folinic acid (leucovorin) F - Fluorouracil (5-FU) OX - Oxaliplatin (Eloxatin)) chemotherapy comprising fluorouracil IV over 46 hours continuously on day 1 and leucovorin calcium IV over 2 hours and oxaliplatin IV over 2 hours on days 1 and 15. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.&#xD;
fluorouracil: Given IV&#xD;
leucovorin calcium: Given IV&#xD;
oxaliplatin: Given IV&#xD;
cetuximab: Given IV&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
        </group>
        <group group_id="E3">
          <title>Arm C</title>
          <description>Patients receive FOLFIRI chemotherapy as in Arm A and bevacizumab IV over 30-90 minutes on days 1 and 15.&#xD;
fluorouracil: Given IV&#xD;
leucovorin calcium: Given IV&#xD;
irinotecan hydrochloride: Given IV&#xD;
bevacizumab: Given IV&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
        </group>
        <group group_id="E4">
          <title>Arm D</title>
          <description>Patients receive FOLFOX chemotherapy as in Arm B and bevacizumab IV over 30-90 minutes on days 1 and 15.&#xD;
fluorouracil: Given IV&#xD;
leucovorin calcium: Given IV&#xD;
oxaliplatin: Given IV&#xD;
bevacizumab: Given IV&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
        </group>
        <group group_id="E5">
          <title>Arm E</title>
          <description>Patients receive CapeIRI (Capecitabine and Irinotecan) chemotherapy comprising capecitabine orally (PO) twice daily (BID) on days 1-14 and irinotecan hydrochloride IV over 90 minutes on days 1 and 8. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.&#xD;
irinotecan hydrochloride: Given IV&#xD;
cetuximab: Given IV&#xD;
capecitabine: Given PO&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
        </group>
        <group group_id="E6">
          <title>Arm F</title>
          <description>Patients receive CapeOX (capecitabine (Xeloda) and oxaliplatin (Eloxatin)) chemotherapy comprising capecitabine PO BID on days 1-14 and oxaliplatin IV over 2 hours on day 1. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.&#xD;
oxaliplatin: Given IV&#xD;
cetuximab: Given IV&#xD;
capecitabine: Given PO&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
        </group>
        <group group_id="E7">
          <title>ARM G</title>
          <description>Patients receive CapeIRI chemotherapy as in Arm E and bevacizumab IV over 30-90 minutes on day 1.&#xD;
irinotecan hydrochloride: Given IV&#xD;
bevacizumab: Given IV&#xD;
capecitabine: Given PO&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
        </group>
        <group group_id="E8">
          <title>Arm H</title>
          <description>Patients receive CapeOX chemotherapy as in Arm F and bevacizumab IV over 30-90 minutes on day 1.&#xD;
oxaliplatin: Given IV&#xD;
bevacizumab: Given IV&#xD;
capecitabine: Given PO&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
        </group>
        <group group_id="E9">
          <title>Arm I</title>
          <description>Patients receive treatment as in Arm D.&#xD;
fluorouracil: Given IV&#xD;
leucovorin calcium: Given IV&#xD;
oxaliplatin: Given IV&#xD;
bevacizumab: Given IV&#xD;
mutation analysis: Correlative studies&#xD;
gene expression analysis: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
nucleic acid sequencing: Correlative studies&#xD;
protein expression analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
DNA analysis: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization - Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <description>Bilateral hands</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea/Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dysguesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Jaw pain</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <description>Scratchy throat</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="4" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Sour stomach</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Flushed face</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle cramps</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Cramping in legs</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <description>At injection site</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sensory neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Parasthesias</sub_title>
                <description>In hands and feet</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Restless legs</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Twitching/restlessness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Too few enrolled participants for meaningful analysis. Study closed prematurely due to slow accrual.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Crystal Denlinger</name_or_title>
      <organization>Fox Chase Cancer Center</organization>
      <phone>215-214-1676</phone>
      <email>crystal.denlinger@fccc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

